Currently, IV busulfan is the gold standard for use as a pre-treatment for stem cell transplantation in AML patients. According to the Center for International Blood and Marrow Transplant Research (CIBMTR), IV busulfan is used in 74% of the patients. Despite the high usage of IV busulfan in this patient population, there are no busulfan …
While busulfan is used to treat patients with chronic myeloid leukemia (CML), it has been demonstrated that imatinib, a tyrosine kinase inhibitor (TKI), has become a cost-effective first-line treatment despite chronic side effects observed in many patients. Serious and cumulative toxicity has been observed with tyrosine kinase inhibitors that had been expected to replace imatinib. …
Normally, red blood cell, white blood cell and platelet levels stay within certain ranges. In aplastic anemia all three of these blood cell levels are low. Treatments for aplastic anemia, which will depend on the severity of your condition and your age, might include observation, blood transfusions, medications, or bone marrow transplantation. Severe aplastic anemia, …
Sickle Cell Anemia and Beta Thalassemia Busulfan may be an important component in CRISPR technology as a conditioning agent to remove diseased cells prior to CRISPR gene editing. A new medical breakthrough gives promise to sickle cell anemia and thalassemia patients using CRISPR-Cas 9 technology, a gene editing technology, with IV busulfan as a conditioning …
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. ALL progresses rapidly and is typically fatal within weeks or months if left untreated. ALL is typically treated initially with chemotherapy aimed at bringing about remission but can be further treated with chemotherapy over a longer period of time. Treatment usually also includes intrathecal …
Approximately 8000 patients per year with multiple myeloma (MM) receive a stem cell transplant in the United States. Ten years ago, the number of transplants were about 5,550. MM is a cancer that affects plasma cells in the bone marrow, causing them to divide rapidly. While melphalan is currently the standard of care, it has …
beta thallasemia
Sickle cell anemia is a serious genetic disease. It is associated with significant pain and often results in stroke, severe infections, progressive organ damage and death, often at a young age. Approximately 25% of all sickle cell anemia patients suffer a stroke prior to age 45. This disease affects about one out of every 365 …
Certain tumors, e.g., breast cancer, malignant melanomas, and multiple myeloma in addition to acute leukemias often spread to the central nervous system. Aside from radiation, which can only be used once, there is no preferred treatment for such tumor involvement. Bulanta, which has an excellent anti- tumor spectrum, can be expected to be effective in …
Beta Thalassemia is a genetic disorder characterized by abnormal hemoglobin production or a shortage of healthy red blood cells. It occurs in 280 million people with at least 439,000 severe cases. This disease is most prevalent among individuals of Mediterranean, South Asia and Middle Eastern descent. Severe Beta thalassemia affects about 1,300 people in the United States. Stem …
